Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report
in Beneficial Microbessudha.ratna@gmail.com
Search for other papers by M. Ratna Sudha in
Current site
Google Scholar
Search for other papers by S. Bhonagiri in
Current site
Google Scholar
Search for other papers by M. Asin Kumar in
Current site
Google Scholar
Abstract
This study was conducted to evaluate the efficacy and safety of Saccharomyces boulardii strain Unique 28 in patients suffering from acute diarrhoea. A total of 25 patients (average age 30.72±4.38 years) with symptoms of acute diarrhoea (≥3 loose motion in last 24 hours for <7 days) were included upon informed consent and ethical committee approval. All subjects were assigned to consume S. boulardii strain Unique 28 (5×109 cfu/capsule) twice a day for a duration of 10 days. Primary outcome measures such as duration of diarrhoea, frequency of defaecation, abdominal pain and consistency of stool were analysed on day 1, 3, 6 and 10 of the study. Secondary outcome measures were evaluated by assessment of incidence and type of adverse events (blood pressure and pulse rate), physical examination and clinical laboratory tests (complete blood count, glutamic-pyruvic transaminase, serum creatinine, stool examination and microscopy and these tests were performed on day 1 and 10 of the study. The results of the present study indicate that the mean duration of diarrhoea decreased from 34.20±4.25 to 9.40±3.00 (P<0.0001) min per day, frequency of defaecation decreased from 7.04±0.84 to 1.76±0.52 (P<0.0001) times a day, abdominal pain decreased from 3.28±1.06 (severe) to 0.72±0.50 (absent) (P<0.0001) and consistency of stool improved from 3.80±0.50 (watery) to 1.32±0.47 (soft) (P<0.0001). In addition, no significant changes in safety parameters were observed during treatment. Therefore, the present study concludes that S. boulardii strain Unique-28 might be useful in alleviating the symptoms of diarrhoea without any adverse effects.
Kauf
Sofortzugang erwerben (PDF-Download und unbegrenzter Online-Zugang):
Institutszugang
Melden Sie sich mit Open Athens, Shibboleth oder Ihren institutionellen Anmeldedaten an.
Persönliche Anmeldung
Melden Sie sich mit Ihrem brill.com-Konto an
-
Bardhan, P.K., Beltinger, J., Beltinger, R.W., Hossain, A., Mahalanabis, D. and Gyr, K., 2000. Screening of patients with acute infectious diarrhoea: evaluation of clinical features, faecal microscopy, and faecal occult blood testing. Scandinavian Journal of Gastroenterology 35: 54-60.
'Screening of patients with acute infectious diarrhoea: evaluation of clinical features, faecal microscopy, and faecal occult blood testing ' () 35 Scandinavian Journal of Gastroenterology : 54 -60.
-
Billoo, A.G., Memon, M.A., Khaskheli, S.A., Murtaza, G., Iqbal, K., Shekhani, S.M. and Siddiqi, A.Q., 2006. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhea. World Journal of Gastroenterology 28: 4557-4560.
'Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhea ' () 28 World Journal of Gastroenterology : 4557 -4560.
-
Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P. and De Meyer, R., 1986. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 20: 192-196.
'Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii ' () 20 Pediatric Research : 192 -196.
-
Buts, J.P., De Keyser, N. and De Raedemaeker, L., 1994. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatric Research 36: 522-527.
'Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines ' () 36 Pediatric Research : 522 -527.
-
Casburn-Jones, A.C. and Farthing, M.J.G., 2004. Management of infectious diarrhea. Gut 53: 296-305.
'Management of infectious diarrhea ' () 53 Gut : 296 -305.
-
Castagliuolo, I., Lamont, J.T., Nikulasson, S.T. and Pothoulakis, C., 1996. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and Immunity 64: 5225-5232.
'Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum ' () 64 Infection and Immunity : 5225 -5232.
-
Czerucka, D. and Rampal, P., 2002. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes and Infection 4: 733-739.
'Experimental effects of Saccharomyces boulardii on diarrheal pathogens ' () 4 Microbes and Infection : 733 -739.
-
Czerucka, D., Piche, T. and Rampal, P., 2007. Yeast as probiotics - Saccharomyces boulardii. Alimentary Pharmacology and Therapeutics 26: 767-778.
'Yeast as probiotics - Saccharomyces boulardii ' () 26 Alimentary Pharmacology and Therapeutics : 767 -778.
-
DeVrese, M. and Marteau, P.R., 2007. Probiotics and prebiotics: effects on diarrhea. Journal of Nutrition 137: 803-811.
'Probiotics and prebiotics: effects on diarrhea ' () 137 Journal of Nutrition : 803 -811.
-
Fuller, R., 1991. Probiotics in human medicine. Gut 32: 439-442.
'Probiotics in human medicine ' () 32 Gut : 439 -442.
-
Golding, B.R. and Gorbach, S.L., 2008. Clinical indications for probiotics: an overview. Clinical Infectious Diseases 46: 96-100.
'Clinical indications for probiotics: an overview ' () 46 Clinical Infectious Diseases : 96 -100.
-
Htwe, K., Yee, K.S., Tin, M. and Vandenplas, Y., 2008. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. American Journal of Tropical Medicine and Hygiene 78: 214-216.
'Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study ' () 78 American Journal of Tropical Medicine and Hygiene : 214 -216.
-
Isolauri, E., 2003. Probiotics for infectious diarrhoea. Gut 52: 436-437.
'Probiotics for infectious diarrhoea ' () 52 Gut : 436 -437.
-
Johnston, B.C., Supina, A.L. and Vohra, S., 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. Canadian Medical Association Journal 175: 377-383.
'Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials ' () 175 Canadian Medical Association Journal : 377 -383.
-
Kurugol, Z. and Koturoglu, G., 2005. Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica 94: 44-47.
'Effects of Saccharomyces boulardii in children with acute diarrhea ' () 94 Acta Paediatrica : 44 -47.
-
Manatsathit, S., Dupont, H.L., Farthing, M., Kositchaiwat, C., Leelakusilvongm, S., Ramakrishna, B.S., Sabra, A., Speelman, P. and Surangsrirat, S., 2002. Guideline for the management of acute diarrhea in adults. Journal of Gastroenterology and Hepatology 17 Suppl. 1: S54-S71.
'Guideline for the management of acute diarrhea in adults ' () 17 Journal of Gastroenterology and Hepatology : S54 -S71.
-
McFarland, L.V. and Bernasconi, P., 1993. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease 6: 157-171.
'Saccharomyces boulardii: a review of an innovative biotherapeutic agent ' () 6 Microbial Ecology in Health and Disease : 157 -171.
-
Salminen, S. and Deighton, M., 1992. Lactic acid bacteria in the gut in normal and disordered states. Digestive Diseases 10: 227-238.
'Lactic acid bacteria in the gut in normal and disordered states ' () 10 Digestive Diseases : 227 -238.
-
Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S. and Black, R., 2006. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials. The Lancet Infectious Diseases 6: 374-382.
'Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials ' () 6 The Lancet Infectious Diseases : 374 -382.
-
Shornikova, A.V., Casas, I.A. and Isolauri, E., 1997. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. Journal of Pediatric Gastroenterology and Nutrition 24: 399-404.
'Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children ' () 24 Journal of Pediatric Gastroenterology and Nutrition : 399 -404.
-
Sudha, R.M., 2011. Safety assessment of Saccharomyces boulardii strain Unique 28 in Sprague-Dawley rats. Beneficial Microbes 2: 221-227.
'Safety assessment of Saccharomyces boulardii strain Unique 28 in Sprague-Dawley rats ' () 2 Beneficial Microbes : 221 -227.
-
World Health Organization (WHO), 1990. The treatment of diarrhoea. A manual for physicians and other senior health workers. World Health Organization, Geneva, Switzerland. Available at: http://whqlibdoc.who.int/publications/2005/9241593180.pdf. http://whqlibdoc.who.int/publications/2005/9241593180.pdf
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 410 | 163 | 13 |
| Gesamttextansichten | 7 | 1 | 0 |
| PDF-Downloads | 13 | 2 | 0 |
Oral consumption of potential probiotic Saccharomyces boulardii strain Unique 28 in patients with acute diarrhoea: a clinical report
in Beneficial Microbessudha.ratna@gmail.com
Search for other papers by M. Ratna Sudha in
Current site
Google Scholar
PubMed
Search for other papers by S. Bhonagiri in
Current site
Google Scholar
PubMed
Search for other papers by M. Asin Kumar in
Current site
Google Scholar
PubMed
Abstract
This study was conducted to evaluate the efficacy and safety of Saccharomyces boulardii strain Unique 28 in patients suffering from acute diarrhoea. A total of 25 patients (average age 30.72±4.38 years) with symptoms of acute diarrhoea (≥3 loose motion in last 24 hours for <7 days) were included upon informed consent and ethical committee approval. All subjects were assigned to consume S. boulardii strain Unique 28 (5×109 cfu/capsule) twice a day for a duration of 10 days. Primary outcome measures such as duration of diarrhoea, frequency of defaecation, abdominal pain and consistency of stool were analysed on day 1, 3, 6 and 10 of the study. Secondary outcome measures were evaluated by assessment of incidence and type of adverse events (blood pressure and pulse rate), physical examination and clinical laboratory tests (complete blood count, glutamic-pyruvic transaminase, serum creatinine, stool examination and microscopy and these tests were performed on day 1 and 10 of the study. The results of the present study indicate that the mean duration of diarrhoea decreased from 34.20±4.25 to 9.40±3.00 (P<0.0001) min per day, frequency of defaecation decreased from 7.04±0.84 to 1.76±0.52 (P<0.0001) times a day, abdominal pain decreased from 3.28±1.06 (severe) to 0.72±0.50 (absent) (P<0.0001) and consistency of stool improved from 3.80±0.50 (watery) to 1.32±0.47 (soft) (P<0.0001). In addition, no significant changes in safety parameters were observed during treatment. Therefore, the present study concludes that S. boulardii strain Unique-28 might be useful in alleviating the symptoms of diarrhoea without any adverse effects.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 410 | 163 | 13 |
| Gesamttextansichten | 7 | 1 | 0 |
| PDF-Downloads | 13 | 2 | 0 |
